» Articles » PMID: 27073399

Microtissues in Cardiovascular Medicine: Regenerative Potential Based on a 3D Microenvironment

Overview
Journal Stem Cells Int
Publisher Wiley
Specialty Cell Biology
Date 2016 Apr 14
PMID 27073399
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

More people die annually from cardiovascular diseases than from any other cause. In particular, patients who suffer from myocardial infarction may be affected by ongoing adverse remodeling processes of the heart that may ultimately lead to heart failure. The introduction of stem and progenitor cell-based applications has raised substantial hope for reversing these processes and inducing cardiac regeneration. However, current stem cell therapies using single-cell suspensions have failed to demonstrate long-lasting efficacy due to the overall low retention rate after cell delivery to the myocardium. To overcome this obstacle, the concept of 3D cell culture techniques has been proposed to enhance therapeutic efficacy and cell engraftment based on the simulation of an in vivo-like microenvironment. Of great interest is the use of so-called microtissues or spheroids, which have evolved from their traditional role as in vitro models to their novel role as therapeutic agents. This review will provide an overview of the therapeutic potential of microtissues by addressing primarily cardiovascular regeneration. It will accentuate their advantages compared to other regenerative approaches and summarize the methods for generating clinically applicable microtissues. In addition, this review will illustrate the unique properties of the microenvironment within microtissues that makes them a promising next-generation therapeutic approach.

Citing Articles

Standardization to Characterize the Complexity of Vessel Network Using the Aortic Ring Model.

Wolint P, Hofmann S, von Atzigen J, Boni R, Miescher I, Giovanoli P Int J Mol Sci. 2025; 26(1.

PMID: 39796147 PMC: 11719671. DOI: 10.3390/ijms26010291.


Tumor Necrosis Factor-Alpha Induces Proangiogenic Profiling of Cardiosphere-Derived Cell Secretome and Increases Its Ability to Stimulate Angiogenic Properties of Endothelial Cells.

Dergilev K, Zubkova E, Guseva A, Tsokolaeva Z, Goltseva Y, Beloglazova I Int J Mol Sci. 2023; 24(23).

PMID: 38068898 PMC: 10706276. DOI: 10.3390/ijms242316575.


Combining Cell Technologies With Biomimetic Tissue Engineering Applications: A New Paradigm for Translational Cardiovascular Therapies.

Motta S, Martin M, Gahwiler E, Visser V, Zaytseva P, Ehterami A Stem Cells Transl Med. 2023; 12(2):72-82.

PMID: 36806699 PMC: 9985110. DOI: 10.1093/stcltm/szad002.


Microphysiological stem cell models of the human heart.

Arslan U, Moruzzi A, Nowacka J, Mummery C, Eckardt D, Loskill P Mater Today Bio. 2022; 14:100259.

PMID: 35514437 PMC: 9062349. DOI: 10.1016/j.mtbio.2022.100259.


Current state and future of 3D bioprinted models for cardiovascular research and drug development.

Polonchuk L, Gentile C ADMET DMPK. 2022; 9(4):231-242.

PMID: 35300373 PMC: 8920100. DOI: 10.5599/admet.951.


References
1.
Menasche P . Stem cells for clinical use in cardiovascular medicine: current limitations and future perspectives. Thromb Haemost. 2005; 94(4):697-701. DOI: 10.1160/TH05-03-0218. View

2.
Lee H, Cho H, Kwon Y, Park Y, Kim H . Phenotypic modulation of human cardiospheres between stemness and paracrine activity, and implications for combined transplantation in cardiovascular regeneration. Biomaterials. 2013; 34(38):9819-29. DOI: 10.1016/j.biomaterials.2013.09.013. View

3.
Guo B, Lei B, Li P, Ma P . Functionalized scaffolds to enhance tissue regeneration. Regen Biomater. 2015; 2(1):47-57. PMC: 4383297. DOI: 10.1093/rb/rbu016. View

4.
Bauer M, Kang L, Qiu Y, Wu J, Peng M, Chen H . Adult cardiac progenitor cell aggregates exhibit survival benefit both in vitro and in vivo. PLoS One. 2012; 7(11):e50491. PMC: 3511575. DOI: 10.1371/journal.pone.0050491. View

5.
Mukherjee N, Chen Z, Sambanis A, Song Y . Effects of cryopreservation on cell viability and insulin secretion in a model tissue-engineered pancreatic substitute (TEPS). Cell Transplant. 2005; 14(7):449-56. DOI: 10.3727/000000005783982882. View